DVAX Quote, Financials, Valuation and Earnings

Edgewise Therapeutics, Inc. has a net margin of 28.38% compared to Dynavax Technologies Corp.'s net margin of --. Dynavax Technologies Corp.'s return on equity of -7.65% beat Edgewise Therapeutics, Inc.'s return on equity of -31.13%.

Dynavax Technologies Corp. has a consensus price target of $20.50, signalling upside risk potential of 33.29%. On the other hand Edgewise Therapeutics, Inc. has an analysts' consensus of $38.17 which suggests that it could grow by 44.85%. Given that Edgewise Therapeutics, Inc. has higher upside potential than Dynavax Technologies Corp., analysts believe Edgewise Therapeutics, Inc. is more attractive than Dynavax Technologies Corp..

Dynavax Technologies Corp. has a beta of 0.886, which suggesting that the stock is 11.435% less volatile than S&P 500. In comparison Edgewise Therapeutics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Dynavax Technologies Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edgewise Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dynavax Technologies Corp. pays -- of its earnings as a dividend. Edgewise Therapeutics, Inc. pays out -- of its earnings as a dividend.

Dynavax Technologies Corp. quarterly revenues are $94.9M, which are larger than Edgewise Therapeutics, Inc. quarterly revenues of --. Dynavax Technologies Corp.'s net income of $26.9M is higher than Edgewise Therapeutics, Inc.'s net income of -$40.7M. Notably, Dynavax Technologies Corp.'s price-to-earnings ratio is 54.00x while Edgewise Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dynavax Technologies Corp. is 6.43x versus -- for Edgewise Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Hyperion DeFi, Inc. has a net margin of 28.38% compared to Dynavax Technologies Corp.'s net margin of --. Dynavax Technologies Corp.'s return on equity of -7.65% beat Hyperion DeFi, Inc.'s return on equity of -143.24%.

Dynavax Technologies Corp. has a consensus price target of $20.50, signalling upside risk potential of 33.29%. On the other hand Hyperion DeFi, Inc. has an analysts' consensus of $5.88 which suggests that it could grow by 53%. Given that Hyperion DeFi, Inc. has higher upside potential than Dynavax Technologies Corp., analysts believe Hyperion DeFi, Inc. is more attractive than Dynavax Technologies Corp..

Dynavax Technologies Corp. has a beta of 0.886, which suggesting that the stock is 11.435% less volatile than S&P 500. In comparison Hyperion DeFi, Inc. has a beta of 2.805, suggesting its more volatile than the S&P 500 by 180.539%.

Dynavax Technologies Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Hyperion DeFi, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dynavax Technologies Corp. pays -- of its earnings as a dividend. Hyperion DeFi, Inc. pays out -- of its earnings as a dividend.

Dynavax Technologies Corp. quarterly revenues are $94.9M, which are larger than Hyperion DeFi, Inc. quarterly revenues of $302.5K. Dynavax Technologies Corp.'s net income of $26.9M is higher than Hyperion DeFi, Inc.'s net income of $6.6M. Notably, Dynavax Technologies Corp.'s price-to-earnings ratio is 54.00x while Hyperion DeFi, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dynavax Technologies Corp. is 6.43x versus 99.53x for Hyperion DeFi, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of 28.38% compared to Dynavax Technologies Corp.'s net margin of 33.68%. Dynavax Technologies Corp.'s return on equity of -7.65% beat Merck & Co., Inc.'s return on equity of 39.63%.

Dynavax Technologies Corp. has a consensus price target of $20.50, signalling upside risk potential of 33.29%. On the other hand Merck & Co., Inc. has an analysts' consensus of $110.04 which suggests that it could grow by 3.05%. Given that Dynavax Technologies Corp. has higher upside potential than Merck & Co., Inc., analysts believe Dynavax Technologies Corp. is more attractive than Merck & Co., Inc..

Dynavax Technologies Corp. has a beta of 0.886, which suggesting that the stock is 11.435% less volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.294, suggesting its less volatile than the S&P 500 by 70.604%.

Dynavax Technologies Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 3.07% to investors and pays a quarterly dividend of $0.85 per share. Dynavax Technologies Corp. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 46.32% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Dynavax Technologies Corp. quarterly revenues are $94.9M, which are smaller than Merck & Co., Inc. quarterly revenues of $17.2B. Dynavax Technologies Corp.'s net income of $26.9M is lower than Merck & Co., Inc.'s net income of $5.8B. Notably, Dynavax Technologies Corp.'s price-to-earnings ratio is 54.00x while Merck & Co., Inc.'s PE ratio is 14.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dynavax Technologies Corp. is 6.43x versus 4.21x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Moderna, Inc. has a net margin of 28.38% compared to Dynavax Technologies Corp.'s net margin of -19.69%. Dynavax Technologies Corp.'s return on equity of -7.65% beat Moderna, Inc.'s return on equity of -30.18%.

Dynavax Technologies Corp. has a consensus price target of $20.50, signalling upside risk potential of 33.29%. On the other hand Moderna, Inc. has an analysts' consensus of $36.75 which suggests that it could grow by 17.79%. Given that Dynavax Technologies Corp. has higher upside potential than Moderna, Inc., analysts believe Dynavax Technologies Corp. is more attractive than Moderna, Inc..

Dynavax Technologies Corp. has a beta of 0.886, which suggesting that the stock is 11.435% less volatile than S&P 500. In comparison Moderna, Inc. has a beta of 1.109, suggesting its more volatile than the S&P 500 by 10.882%.

Dynavax Technologies Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dynavax Technologies Corp. pays -- of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend.

Dynavax Technologies Corp. quarterly revenues are $94.9M, which are smaller than Moderna, Inc. quarterly revenues of $1B. Dynavax Technologies Corp.'s net income of $26.9M is higher than Moderna, Inc.'s net income of -$200M. Notably, Dynavax Technologies Corp.'s price-to-earnings ratio is 54.00x while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dynavax Technologies Corp. is 6.43x versus 5.41x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.